Skip to main content
    Health Library

    Weight management · 5 min read · Evidence-informed guide

    Semaglutide vs. Tirzepatide: What Is the Difference?

    Semaglutide and tirzepatide are different prescription medicines with different mechanisms and FDA-approved products. Semaglutide is a GLP-1 receptor agonist; tirzepatide acts at GIP and GLP-1 receptors. The appropriate option depends on diagnosis, risks, other medicines, access, and treatment goals.

    Key answer

    The short version

    Semaglutide and tirzepatide are different prescription medicines with different mechanisms and FDA-approved products. Semaglutide is a GLP-1 receptor agonist; tirzepatide acts at GIP and GLP-1 receptors. The appropriate option depends on diagnosis, risks, other medicines, access, and treatment goals.

    Brand names do not mean the same indication

    A medicine’s brand, dose form, and FDA-approved indication matter. Ozempic and Mounjaro are approved for type 2 diabetes; Wegovy and Zepbound have chronic weight-management indications for qualifying patients.

    Selection is a clinical decision

    A clinician considers medical history, diabetes status, gastrointestinal symptoms, kidney and gallbladder history, pregnancy plans, drug interactions, coverage, and the ability to maintain follow-up.

    Avoid “best medicine” marketing

    No online comparison can determine what is safest or appropriate for an individual. Discuss evidence, expected benefits, uncertainties, adverse effects, cost, and alternatives in a clinical visit.

    Clinical perspective

    How to think about this

    Prescription weight management is longitudinal medical care, not a consumer transaction. A sound plan weighs approved use, safety, nutrition, access, follow-up, and the patient’s own goals; it should never reduce a complex health decision to a promised outcome or a single number on a scale.

    Questions worth bringing to a visit

    • What FDA-approved option, if any, fits my clinical situation?
    • What safety monitoring and follow-up would I need?
    • How will we assess benefit, tolerability, and access over time?

    Continue exploring

    Related patient questions

    GLP-1 Weight-Loss Medicines: Questions to AskRead article Who May Qualify for GLP-1 Weight-Loss Medicine?Read article GLP-1 Side Effects: What to Discuss Before StartingRead article

    Sources

    1. 1. FDA, Wegovy Prescribing Information

      Current semaglutide product indication, warnings, and dosing information.

    2. 2. FDA, Zepbound approval for chronic weight management

      Tirzepatide chronic weight-management approval context.